Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCM-181
- Development stage
- Unknown
- Lead developer
- Yunnan Shunxi Regenerative Medicine Engineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
SCM-181 is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by Yunnan Shunxi Regenerative Medicine Engineering for the treatment of idiopathic pulmonary fibrosis (IPF). The therapy utilizes the innate ability of mesenchymal stem cells to home to sites of injury and exert potent immunomodulatory, anti-inflammatory, and anti-fibrotic effects. In the context of IPF, SCM-181 is designed to modulate the aberrant immune response and inhibit the activation of myofibroblasts, thereby slowing the progression of lung scarring and promoting the repair of damaged alveolar structures. The product received IND approval from the China National Medical Products Administration (NMPA) and is currently undergoing clinical evaluation to assess its safety and efficacy in patients with chronic fibrotic lung diseases.
- Other names
- umbilical cord-derived mesenchymal stem cellsUC-MSCs
Beyond the preview
Go deeper on SCM-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCM-181.